Publications by authors named "Kazunori Kohara"
To clarify the cumulative recurrence-free interval and survival rate with hepatitis C virus (HCV)-related single, small hepatocellular carcinoma (HCC), we studied 32 patients with surgical resection, 61 with ablation therapy and 28 with transcatheter chemoembolization (TACE). A log-rank test revealed that there were no significant differences in the recurrence-free interval (p = 0.08) and survival (p = 0.
View Article and Find Full Text PDFArticle Synopsis
- Aspirin (ASA) was found to inhibit the growth of human hepatoma SKHep-1 cells in a time- and dose-dependent manner.
- An increase in intracellular hydrogen peroxide (H(2)O(2)) levels was detected as soon as 15 minutes after ASA treatment, which correlated with the induction of cell death (apoptosis).
- The presence of a catalase inhibitor enhanced the apoptotic effect of ASA on SKHep-1 cells, suggesting that H(2)O(2) plays a significant role in this process.
The purpose of this pilot study was to evaluate the efficacy and adverse events of systemic combined chemotherapy with low dose of 5-fluorouracil (250 mg/m2, 5 days), cisplatin (10 mg/m2, 5 days), and interferon-alpha (2.5 million units, three times weekly) for advanced hepatocellular carcinoma (HCC) underlying liver cirrhosis. Six patients who had advanced HCC with tumor thrombi in the main portal trunk were enrolled in this study.
View Article and Find Full Text PDFBackground: The objectives of this study were to clarify risk factors for local tumor recurrence and to determine which patients with hepatocellular carcinoma (HCC) are most suitable for a single session, single application of percutaneous radiofrequency (RF) ablation.
Methods: Fifty-six consecutive patients with 65 HCC tumors measuring
To determine whether previous IFN therapy for chronic hepatitis C (HCV) infection influences the outcome of patients with hepatocellular carcinoma (HCC), 143 patients were enrolled in this study. Of 143 patients, 48 had received previous IFN therapy (IFN group) and the remaining 95 had not (untreated group). We estimated distant intrahepatic recurrence-free intervals and disease-specific survivals of the two groups by the Kaplan-Meier method and analyzed the difference by the log-rank test.
View Article and Find Full Text PDFArticle Synopsis
- Arsenic trioxide (As(2)O(3)) shows promise in treating acute promyelocytic leukemia and has been studied for its effects on human liver cancer cell lines, specifically SK-Hep-1, HepG2, and HuH7.
- In HuH7 cells, As(2)O(3) significantly decreased cell proliferation in a dose-dependent manner, while SK-Hep-1 and HepG2 cells were inhibited at higher concentrations.
- The study found that the effectiveness of As(2)O(3) is linked to the levels of intracellular glutathione (GSH), suggesting that lowering GSH could enhance the drug's sensitivity, indicating its potential as a treatment for hepatocellular carcinoma